Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19

Overview

Journal Mol Biotechnol

Publisher Springer

Specialties Biotechnology
Molecular Biology

Date 2021 Feb 24

PMID 33625681

Citations 11

Authors

Seyed Mehdi Sadat

Mohammad Reza Aghadadeghi

Masoume Yousefi

Arezoo Khodaei

Mona Sadat Larijani

Golnaz Bahramali

Affiliations

Soon will be listed here.

Abstract

The emerging Coronavirus Disease 2019 (COVID-19) pandemic has posed a serious threat to the public health worldwide, demanding urgent vaccine provide. According to the virus feature as an RNA virus, a high rate of mutations imposes some vaccine design difficulties. Bioinformatics tools have been widely used to make advantage of conserved regions as well as immunogenicity. In this study, we aimed at immunoinformatic evaluation of SARS-CoV-2 proteins conservancy and immunogenicity to design a preventive vaccine candidate. Spike, Membrane and Nucleocapsid amino acid sequences were obtained, and four possible fusion proteins were assessed and compared in terms of structural features and immunogenicity, and population coverage. MHC-I and MHC-II T-cell epitopes, the linear and conformational B-cell epitopes were evaluated. Among the predicted models, the truncated form of Spike in fusion with M and N protein applying AAY linker has high rate of MHC-I and MCH-II epitopes with high antigenicity and acceptable population coverage of 82.95% in Iran and 92.51% in Europe. The in silico study provided truncated Spike-M-N SARS-CoV-2 as a potential preventive vaccine candidate for further in vivo evaluation.

Citing Articles

Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran.

Sadat Larijani M, Biglari A, Sorouri R, Salehi-Vaziri M, Doroud D, Azadmanesh K Iran Biomed J. 2024; 28(1):1-7.

PMID: 38224028 PMC: 10994636. DOI: 10.61186/ibj.3964.

Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine.

Farahmand B, Sadat Larijani M, Fotouhi F, Biglari A, Sorouri R, Bagheri Amiri F Heliyon. 2023; 9(10):e20555.

PMID: 37810803 PMC: 10551543. DOI: 10.1016/j.heliyon.2023.e20555.

Mapping Potential Vaccine Candidates Predicted by VaxiJen for Different Viral Pathogens between 2017-2021-A Scoping Review.

Salod Z, Mahomed O Vaccines (Basel). 2022; 10(11).

PMID: 36366294 PMC: 9695814. DOI: 10.3390/vaccines10111785.

SARS-CoV-2 Viral Shedding and Associated Factors among COVID-19 Inpatients and Outpatients.

Sofian M, Khansarinejad B, Ghaznavi-Rad E, Shokoohi F, Mazaherpour H, Farmani F Interdiscip Perspect Infect Dis. 2022; 2022:1411106.

PMID: 35734510 PMC: 9207016. DOI: 10.1155/2022/1411106.

EpiBuilder: A Tool for Assembling, Searching, and Classifying B-Cell Epitopes.

Moreira R, Benetti Filho V, Calomeno N, Wagner G, Miletti L Bioinform Biol Insights. 2022; 16:11779322221095221.

PMID: 35571557 PMC: 9102138. DOI: 10.1177/11779322221095221.

References

Huang Y, Yang C, Xu X, Xu W, Liu S . Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020; 41(9):1141-1149. PMC: 7396720. DOI: 10.1038/s41401-020-0485-4. View

Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E, Vandecandelaere P . Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin Microbiol Infect. 2020; 26(11):1557.e1-1557.e7. PMC: 7834107. DOI: 10.1016/j.cmi.2020.07.038. View

Turonova B, Sikora M, Schurmann C, Hagen W, Welsch S, Blanc F . In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Science. 2020; 370(6513):203-208. PMC: 7665311. DOI: 10.1126/science.abd5223. View

Alexpandi R, De Mesquita J, Pandian S, Veera Ravi A . Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An Analysis. Front Microbiol. 2020; 11:1796. PMC: 7390959. DOI: 10.3389/fmicb.2020.01796. View

Trigueiro-Louro J, Correia V, Figueiredo-Nunes I, Giria M, Rebelo-de-Andrade H . Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike. Comput Struct Biotechnol J. 2020; 18:2117-2131. PMC: 7452956. DOI: 10.1016/j.csbj.2020.07.017. View

Siu Y, Teoh K, Lo J, Chan C, Kien F, Escriou N . The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol. 2008; 82(22):11318-30. PMC: 2573274. DOI: 10.1128/JVI.01052-08. View

Liu D, Yuan Q, Liao Y . Coronavirus envelope protein: a small membrane protein with multiple functions. Cell Mol Life Sci. 2007; 64(16):2043-8. PMC: 7079843. DOI: 10.1007/s00018-007-7103-1. View

Mukherjee S, Bhattacharyya D, Bhunia A . Host-membrane interacting interface of the SARS coronavirus envelope protein: Immense functional potential of C-terminal domain. Biophys Chem. 2020; 266:106452. PMC: 7418743. DOI: 10.1016/j.bpc.2020.106452. View

Astuti I, Ysrafil . Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr. 2020; 14(4):407-412. PMC: 7165108. DOI: 10.1016/j.dsx.2020.04.020. View

10.

Kang S, Yang M, Hong Z, Zhang L, Huang Z, Chen X . Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B. 2020; 10(7):1228-1238. PMC: 7194921. DOI: 10.1016/j.apsb.2020.04.009. View

11.

Surjit M, Lal S . The SARS-CoV nucleocapsid protein: a protein with multifarious activities. Infect Genet Evol. 2007; 8(4):397-405. PMC: 7106238. DOI: 10.1016/j.meegid.2007.07.004. View

12.

Amrun S, Lee C, Lee B, Fong S, Young B, Chee R . Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine. 2020; 58:102911. PMC: 7375792. DOI: 10.1016/j.ebiom.2020.102911. View

13.

Tuttle K . Impact of the COVID-19 pandemic on clinical research. Nat Rev Nephrol. 2020; 16(10):562-564. PMC: 7404075. DOI: 10.1038/s41581-020-00336-9. View

14.

Torreele E . The rush to create a covid-19 vaccine may do more harm than good. BMJ. 2020; 370:m3209. DOI: 10.1136/bmj.m3209. View

15.

Prompetchara E, Ketloy C, Palaga T . Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020; 38(1):1-9. DOI: 10.12932/AP-200220-0772. View

16.

Moreno-Fierros L, Garcia-Silva I, Rosales-Mendoza S . Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?. Expert Opin Biol Ther. 2020; 20(8):831-836. DOI: 10.1080/14712598.2020.1767062. View

17.

Chakraborty C, Sharma A, Sharma G, Bhattacharya M, Lee S . SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci. 2020; 24(7):4016-4026. DOI: 10.26355/eurrev_202004_20871. View

18.

Chakraborty C, Sharma A, Sharma G, Bhattacharya M, Saha R, Lee S . Extensive Partnership, Collaboration, and Teamwork is Required to Stop the COVID-19 Outbreak. Arch Med Res. 2020; 51(7):728-730. PMC: 7260497. DOI: 10.1016/j.arcmed.2020.05.021. View

19.

Amanat F, Krammer F . SARS-CoV-2 Vaccines: Status Report. Immunity. 2020; 52(4):583-589. PMC: 7136867. DOI: 10.1016/j.immuni.2020.03.007. View

20.

Chakraborty C, Sharma A, Bhattacharya M, Sharma G, Lee S, Agoramoorthy G . Consider TLR5 for new therapeutic development against COVID-19. J Med Virol. 2020; 92(11):2314-2315. PMC: 7272826. DOI: 10.1002/jmv.25997. View